Treatment with Sulodexide Downregulates Biomarkers for Endothelial Dysfunction in Convalescent COVID-19 Patients
Clinical and Applied Thrombosis/Hemostasis · 2025-01 · 31
DOI: 10.1177/10760296241297647 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, online erschienen am 07.01.2025. Verfasst von Alejandro J Gonzalez-Ochoa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Vascular Surgery Department, Centro Médico del Noroeste, San Luis Rio Colorado, Sonora, México. Hauptthemen laut MEDLINE: Biomarkers, COVID-19, COVID-19 Drug Treatment, Endothelium, Vascular. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Alfasigma SpA.
Abstract (Originalsprache)
Introduction
Persistent elevation of biomarkers associated with endothelial dysfunction in convalescent COVID-19 patients has been linked to an increased risk of long-term cardiovascular complications, including long COVID syndrome. Sulodexide, known for its vascular endothelial affinity, has demonstrated pleiotropic protective properties. This study aims to evaluate the impact of sulodexide on serum levels of endothelial dysfunction biomarkers in patients during the convalescent phase of COVID-19.
Methods
We conducted a double-blind, single-center, randomized, placebo-controlled trial in Mexico, comparing sulodexide (250 LRU orally, twice daily) with placebo over 8 weeks in adult patients during early COVID-19 convalescence. Differences in serum biomarkers between the groups were analyzed using repeated measures and post hoc tests, with Thrombomodulin (TM) as the primary endpoint.
Results
Among 206 analyzed patients (103 in each group), at week 8, the sulodexide group exhibited significantly lower mean levels of Thrombomodulin (TM) (25.2 ± 7.9 ng/mL vs 29.9 ± 14.7 ng/mL, P = .03), von Willebrand Factor (vWF) (232 ± 131 U/dL vs 266 ± 122 U/dL, P = .02) and Interleukin-6 (IL-6) (12.5 ± 13.2 pg/mL vs 16.2 ± 16.5 pg/mL, P = .03) compared to the placebo group. D-dimer and C reactive protein (CRP) in the sulodexide group were also lowered. No significant differences were observed for P-selectin, fibrinogen, VCAM-1, or ICAM-1 levels.
Conclusions
Patients in the convalescent phase of COVID-19 who received sulodexide for eight weeks showed a reduction in TM, vWF, D-dimer, CRP, and IL-6 serum levels compared to placebo. These findings suggest a potential protective effect of sulodexide against thromboinflammation and endothelial damage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vascular Surgery Department, Centro Médico del Noroeste, San Luis Rio Colorado, Sonora, México.
- Vascular and Endovascular Surgery department, CLINEDEM, San Luis Rio Colorado, Sonora, México.
- Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
- Otorhinolaryngology department, CLINEDEM, San Luis Rio Colorado, Sonora, México.
- Hemostasis and Thrombosis Research Laboratories, Loyola University Medical Center, Maywood, Illinois, USA.
ORCID-Profile: Alejandro J Gonzalez-Ochoa, Gyozo Szolnoky, Jawed Fareed
Förderung
- Alfasigma SpA
Zitieren
APA
Gonzalez-Ochoa, A. J., Szolnoky, G., Hernandez-Ibarra, A. G., & Fareed, J. (2025). Treatment with Sulodexide Downregulates Biomarkers for Endothelial Dysfunction in Convalescent COVID-19 Patients. Clinical and Applied Thrombosis/Hemostasis, 31. https://doi.org/10.1177/10760296241297647
Vancouver
Gonzalez-Ochoa AJ, Szolnoky G, Hernandez-Ibarra AG, Fareed J. Treatment with Sulodexide Downregulates Biomarkers for Endothelial Dysfunction in Convalescent COVID-19 Patients. Clinical and Applied Thrombosis/Hemostasis. 2025;31. doi:10.1177/10760296241297647
BibTeX
@article{GonzalezOchoa2025,
author = {Gonzalez-Ochoa, Alejandro J and Szolnoky, Gyozo and Hernandez-Ibarra, Ana G and Fareed, Jawed},
title = {Treatment with Sulodexide Downregulates Biomarkers for Endothelial Dysfunction in Convalescent COVID-19 Patients},
journal = {Clinical and Applied Thrombosis/Hemostasis},
year = {2025},
volume = {31},
doi = {10.1177/10760296241297647}
}
EUVIMED